WuXi AppTec: Intends to Transfer 98.9% of Equity in Huaxin Pharmaceutical to WuXi Research and Development

On the evening of September 2, WuXi AppTec announced that in order to optimize its organizational structure, the company has decided to transfer a portion of its subsidiary's equity to a newly established domestic wholly-owned subsidiary. The company plans to transfer 98.9% of the shares of Shanghai Hequan Pharmaceutical Co., Ltd., currently held by Shanghai WuXi AppTec New Drug Development Co., Ltd., to WuXi AppTec Pharmaceutical Research and Development Co., Ltd. After the equity transfer is completed, WuXi Research will directly hold 98.9% of Hequan Pharmaceutical's shares. This equity transfer does not involve changes in the company's consolidated financial statements, and does not change the substantive business activities of Hequan Pharmaceutical.